Psychemedics Corporation (PMD) |
| 2.67 2.67 (100%) 02-10 16:00 |
| Open: | 2.67 |
| High: | 2.67 |
| Low: | 2.67 |
| Volume: | 112,269 |
| Market Cap: | 16(M) |
| PE Ratio: | -5.24 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Medical - Diagnostics & Research |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 11.67 |
| Resistance 1: | 9.99 |
| Pivot price: | 9.50 |
| Support 1: | 9.17 |
| Support 2: | 8.66 |
| 52w High: | 2.67 |
| 52w Low: | 2.6 |
Established in 1986 and based in Acton, Massachusetts, Psychemedics Corporation specializes in providing comprehensive drug abuse detection services. The company operates across the United States, Brazil, and various international locations, employing hair sample analysis to identify a broad spectrum of substances. Their rigorous testing methodology involves both initial screening and confirmatory analysis through mass spectrometry, adhering to recognized industry standards. Psychemedics' analytical capabilities cover a wide array of drugs, including common illicit substances like cocaine, marijuana, and PCP. They also detect various amphetamines, such as ecstasy, eve, and Adderall, along with a comprehensive list of opiates, including heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine. Furthermore, their tests identify synthetic cannabinoids (e.g., K2, Spice, Blaze), benzodiazepines (like Xanax, Valium, and Ativan), nicotine, and Fentanyl. The results of their analyses offer more than just a positive or negative finding; they provide quantitative data indicating the approximate amount of drug consumed. Crucially, the tests also yield historical information that can reveal an individual's drug use patterns over an extended period. Psychemedics serves a diverse clientele, including employers seeking applicant and employee drug screening, treatment professionals, law enforcement agencies, school administrators, and parents concerned about potential substance use by their children.
| EPS | -0.690 |
| Book Value | 11.850 |
| PEG Ratio | 16.74 |
| Gross Profit | 2.706 |
| Profit Margin (%) | -15.28 |
| Operating Margin (%) | 13.11 |
| Return on Assets (ttm) | 1.2 |
| Return on Equity (ttm) | -5.7 |
Tue, 07 Jul 2026
Psychemedics Corp highlights hair-based drug testing business. PMD positions itself in forensic and - ad-hoc-news.de
Tue, 30 Jun 2026
Psychemedics says student drug positivity hit 5-year low at 3.1% - Stock Titan
Mon, 18 Nov 2024
Psychemedics Corporation Reminds Stockholders to Cast Their Votes for Upcoming Annual Meeting of Stockholders - GlobeNewswire
Tue, 02 Jan 2024
Small cap drug testing company relocates HQ to DFW from Massachusetts - The Business Journals
Wed, 12 Jul 2023
Psychemedics Corporation Announces CEO Succession Plan - citybiz
Thu, 09 Jun 2022
Psychemedics Nominates Peter Kamin and Darius Nevin to Serve as Members of its Board - citybiz
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |